| RRC ID |
83110
|
| 著者 |
Ohue Y, Kurose K, Nozawa R, Isobe M, Nishio Y, Tanaka T, Doki Y, Hori T, Fukuoka J, Oka M, Nakayama E.
|
| タイトル |
Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells.
|
| ジャーナル |
Cancer Immunol Res
|
| Abstract |
The immune status of tumors varies, and this may affect the overall survival (OS) of patients. We examined tumors from 120 patients with lung adenocarcinomas with a tissue microarray for T-cell infiltration and the expression of PD-L1 and Galectin-9 (both ligands for inhibitory receptors on T cells), and cancer/testis (CT) antigen XAGE1 (GAGED2a; a tumor antigen often found on lung tumors) expression, to determine their relevance to OS. Patients defined as pStage I-IIIA could be grouped, based on the expression profiles of PD-L1, Galectin-9, and XAGE1, into cluster A, who had prolonged survival, and cluster B, who had shorter survival. The difference in survival of the clusters was confirmed separately for pStage I and pStage II-IIIA patients. Cluster A patients who also had CD4 and CD8 T-cell infiltration showed even better survival, as expected. The findings were confirmed by examining an independent validation cohort of 68 pStage I lung adenocarcinoma patients. Our data showed that PD-L1 expression was a positive indicator, whereas Galectin-9 and XAGE1 expression was negative. In vitro analyses suggested that PD-L1 expression was upregulated by IFNγ secreted from activated T cells in the tumor and Galectin-9 expression was counteracting those T cells. Thus, use of these immune markers enables the creation of a discriminant function with which to classify tumors and predict survival. Cancer Immunol Res; 4(12); 1049-60. ©2016 AACR.
|
| 巻・号 |
4(12)
|
| ページ |
1049-1060
|
| 公開日 |
2016-12-1
|
| DOI |
10.1158/2326-6066.CIR-15-0266
|
| PII |
2326-6066.CIR-15-0266
|
| PMID |
27799141
|
| MeSH |
Adenocarcinoma / immunology
Adenocarcinoma / metabolism*
Adenocarcinoma of Lung
Afatinib
Antigens, Neoplasm / metabolism*
B7-H1 Antigen / metabolism*
Biomarkers, Tumor / metabolism
CD4-Positive T-Lymphocytes / immunology
CD4-Positive T-Lymphocytes / metabolism
CD8-Positive T-Lymphocytes / immunology
CD8-Positive T-Lymphocytes / metabolism
Cell Line, Tumor
ErbB Receptors / antagonists & inhibitors
Galectins / metabolism*
Humans
Lung Neoplasms / immunology
Lung Neoplasms / metabolism*
Lymphocytes, Tumor-Infiltrating / immunology
Lymphocytes, Tumor-Infiltrating / metabolism
Quinazolines / pharmacology
Receptor, ErbB-2 / antagonists & inhibitors
Survival Analysis
|
| IF |
8.728
|
| リソース情報 |
| ヒト・動物細胞 |
PC-9(RCB4455)
II-18(RCB2093)
A549(RCB0098)
HLC-1(RCB0083)
Sq-1(RCB1905)
EBC-1(RCB1965)
RERF-LC-AI(RCB0444) |
